Impact of Weight Loss on Improvement of Insulin Resistance and Reduction of Fatty Hepatic Steatosis in Obese Patients with Type 2 Diabetes
Main Article Content
Abstract
Background: Obesity and type 2 diabetes mellitus (T2DM) are common metabolic disorders requiring effective non-pharmacological interventions. This study evaluated the effects of a regular dietary intervention program on anthropometric, body composition, and biochemical indicators using a randomized complete block design. Methods: Three groups were included: healthy control, infected (untreated) control, and experimental (dietary program). Anthropometric measures (BMI, BFM, VFA, TBW, protein, minerals, BMR), glycemic indicators (glucose, insulin, HbA1c, HOMA-IR, C-peptide), and liver enzymes (AST, ALT, ALP, GGT) were assessed using SPSS v26. Results: The infected group showed significant elevations in BMI (33.23), BFM (35.70), VFA (171.78 cm²), glucose (176.01 mg/dL), HbA1c (8.52%), and C-peptide. The experimental group demonstrated marked improvement: reduced BMI, a ~34% decrease in VFA, a 16.2% decline in glucose (147.45 mg/dL), and an HbA1c reduction to 7.44% — clinically significant, as each 1% reduction in HbA1c lowers cardiovascular risk. C-peptide decreased, reflecting improved β-cell function. Liver enzymes remained within normal ranges, indicating reduced hepatic fat and inflammation. Conclusion: Regular dietary intervention significantly improved anthropometric, glycemic, and metabolic indicators in obese T2DM individuals, though values did not fully normalize. These findings support structured dietary programs as effective interventions for managing obesity-related metabolic dysfunction.
Article Details
Section
How to Cite
References
1. Cem Sulu and Volkan Demirhan Yumuk (2024). Treat Obesity to Treat Type 2 Diabetes Mellitus. Diabetes Therapy. Springer, Volume 15, pages 611–622.
2. Jalili, V., Zohreh P, Naeemeh H A, Maryam G, Marjan A, Anahita H, Azadeh H, Fatemeh S, Atiyeh A, Zohreh M, Hanieh S, Mina E, and Saeid D. (2022). Association between obesity and serum levels of liver function biomarkers. BMC Endocrine Disorders, 22, 285.
3. Xu Yang, Qi fang Meng and Pingyu Wu (2025).Effects of Weight Loss on Insulin Resistance and Liver Health in T2DM and NAFLD Patients. Med Sci Monit, v 31: e947157.
4. Han Fang, Fernando F. Anheˆ Dana, Andre´ Tchernof, Andre´ Marette, Jonathan D. Schertzer (2025). Gut substrate trap of D-lactate from microbiota improves blood glucose and fatty liver disease in obese mice. Cell Metabolism 37, 1806–1819
5. Bing Zhou, Yunchen Luo, Hanqi Bi, Yao Li, Cheng Hu, and Yan Lu (2024). Amelioration of nonalcoholic fatty liver disease by inhibiting the deubiquitinating enzyme RPN11.Cell Metabolism 36, 2228–2244.
6. Shehab M Abd El-Kader, and Osama H Al-Jiffri (2018). Impact of weight reduction on insulin resistance, adhesive molecules, and adipokines dysregulation among obese type 2 diabetic patients. African Health Sciences Vol 18 Issue 4:873-883.
7. Inha Jung, Dae-Jeong Koo, Won-Young Lee. (2024) Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective. Diabetes Meta J ,48:327-339.
8. Lucia Mastrototaro and Michael Rodena (2021).Insulin resistance and insulin-sensitizing agents. Metabolism Clinical and Experimental 125 (2021) 154892.
9. Chikara K, Kyoichiro T, Kumiko Shiba, Yasutaka M, Shunsaku F, Noriko Shimazu, S Yamaguchi, Kazuo Kanno, and Yoshihiro Ogawa. (2016). Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLOS ONE 11(3):e015151
10. Francisca Contreras, Werd Al-Najim, and Carel W. le Roux. (2024). Health Benefits Beyond the Scale: The Role of Diet and Nutrition During Weight Loss Programs. Nutrients 2024, 16, 3585.
11. Sirwan K Ahmed and Ribwar A Mohammed. (2025). Obesity: Prevalence, causes, consequences, management, preventive strategies, and future research directions. Metabolism Open 27: 100375.
12. Diego G, Ramesh K, Angel Noe, Hector J Maldonado-Garzaa, and Jesus Z (2023). TagedH1Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents. Annals of Hepatology 28:100751
13. Agustinus I. H., Anak A. S. M. Prabandar, Desak M., Wayan W., Tjokorda G. Agung, Ni Nyoman, Luh P. R., and Christopher R. (2025). Association between phase angle and ECW/TBW ratio with body composition in individuals with central obesity: a cross-sectional study. Frontiers in Nutrition. 12:1638075.
14. Aliyu, U., Salman M. Toor, Ibrahim A, Mohamed A. E, Abdul Badi Abou−Samra, and Omar M. E. Albagha (2025). Evaluating indices of insulin resistance and estimating the global prevalence of IR. Frontiers in Endocrinology, 16, 1591677.
15. Uchenna N. Ijoma, Paschal O. Njoku, Ejikeme B. Arodiwe, Chinwuba K. Ijoma (2020). Increasing Trend of Overweight and Obesity in a Rural Community in South East Nigeria. Open Journal of Epidemiology, Vol. 10 No.3:P.323-333.
16. Gallagher, D, Heymsfield, S B., M Heo, S. A. Jebb, Murgatroyd P R, Y Sakamoto (2000). Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr. 72(3):694-701. DOI: 10.1093/ajcn/72.3.694.
17. Arang Lee, Ye Ji Kim, Seung-Won Oh, et al (2018). Cut-Off Values for Visceral Fat Area Identifying Korean Adults at Risk for Metabolic Syndrome. Korean Journal of Family Medicine 39(4):239-246.
18. Mengwei Li, Xiaowei Chi, Ying Wang, Sarra S, Wenwei Xie, and Hanmei Xu (2022). Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduction and Targeted Therapy 7: 216
19. Inha Jung, Dae-Jeong Koo, Won-Young Lee (2024). Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Respective. Diabetes Meta J v 48:327-339.
20. Gijsen, M., Eline S, Pieter De Cock, Manu L.N.G. Malbrain, Joost W, Isabel S (2021). Reproducibility of fluid status measured by BIA in healthy adults. Advances in Clinical and Experimental Medicine, 30(10), 1053–1061.
21. Baris Karagun and Nuh Baklacı (2024). Comparative analysis of basal metabolic rate Measurement methods in overweight and obese individuals. Medicine Journal, volume 103:35.
22. Farkas, G. J, Phillip S. G., Naraka T, Ashraf S. G., David R. D., Eduard T 1, Arthur S. B., and David R. G. (2021). Comparison of various indices in identifying insulin resistance. Journal of Clinical Medicine, 10(24), 5935.
23. Deirdre K. Tobias, Jordi Merino, Abrar Ahmad, Catherine Aiken, Jamie L. Benham, Dhanasekaran Bodhini, et al (2023). Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nature Medicine, Volume pp: 2438–2457.
24. Shuo F, Renming Liu, Christopher Th, Brian C, Sunghyun Ch, Adam B, and Huishan W. (2025). Effects of carbohydrate-restricted diets and macronutrient replacements on cardiovascular health and body composition in adults: a meta-analysis of randomized trials. The American Journal of Clinical Nutrition 122 1461–1478.
25. Shaopeng Ming, Chunrong Zeng, Haiming Wen, Zhaoyu Li, Hongtao Liu, and Ke Qin. (2024). Association between Body Mass Index and Early Renal Function after Kidney Transplantation: Observational and Mendelian Randomization Study. Obes Facts 17:459–472.
26. Dominika M, Jacek S, Anna B-K, Katarzyna S.E, Aleksandra C, and Andrzej D. (2023). Evaluation of Nutritional Status and the Impact of Nutritional Treatment in Patients with Pancreatic Cancer. Cancers vol, 15, 3816.
27. Christopher J. Oliver, Mike C, Nedeljka R, Anja B-W, Grant T, and Stephen Myers (2025). Fat-Free Mass: Friend or Foe to Metabolic Health? Journal of Cachexia, Sarcopenia and Muscle, vol 16: e13714.
28. Rexiati R, Jianlu Song, Tiantong Liu, Yuan Chen, Xi Zou, Ruiyuan Xu, Qiang Xu, Xinpeng Yin, and Qiang Xu. (2023). Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front. Endocrinal. 14:1161521. doi: 10.3389/fendo.2023.1161521.
29. Dipti Tiwari and Tar Choon Aw. (2024). The 2024 American Diabetes Association guidelines on Standards of Medical Care in Diabetes: key takeaways for laboratory. Explor Endocr Metab Dis. Vol,1:158–66.
30. Shin-Hae Lee1, Shi-Young Park1, and Cheol Soo Choi. (2022). Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes Metab J vol,46:15-37.
31. Aleksandra Leziak, Julia Lipina, Magdalena Reclik, and Piotr Kocelak (2025). Dietary Modulation of Metabolic Health: From Bioactive Compounds to Personalized Nutrition. Metabolites vol, 15, p. 624.
32. Xuefei Zhao, Xuedong An, Cunqing Yang, Wenjie Sun, Hangyu Ji, and Fengmei Lian. (2023). The crucial role and mechanism of insulin resistance in metabolic disease. Front. Endocrinol. 14:1149239.
33. Israa M. Ali Alameen, Sumayah Mahmood Rafid, Baqer K. Hothefa, and Farah Ali Hameed (2026). HbA1c, C-Peptide, and Other Biochemical Indicators in the Management of Type 1 Diabetes Mellitus: A Review. HILLA UNIV COLL J MED SCI vol,4, p:67–80.
34. Marcus Lind, Henrik Imberg, Ruth L. Coleman, Olle Nerman, and Rury R. Holman (2021). Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Diabetes Care Volume 44, p. 2231-2237.
35. Jamiołkowska-Sztabkowska, M., Barbara G-O, and Artur Bossowski. (2021). C-peptide and residual β-cell function in pediatric diabetes. Pediatric Endocrinology, Diabetes and Metabolism, 27(2), 109–118.
36. Samar A. Antar, Nada A. Ashour, Marwa Sharaky, Muhammad Khattab, Naira A. Ashour, Roaa T. Zaid, Eun Joo Roh, Ahmed Elkamhawy, and Ahmed A. Al-Karmalawy (2023). Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomedicine & Pharmacotherapy, Volume 168, 115734
37. Ali, N., Abu H S, Khandaker A F, M Asaduzzaman, Rahanuma R K, Noyan H M, Ananya D M, Zitu B, Mahmudul H, Rakib M & Farjana I. (2021). Serum liver enzymes and general/abdominal obesity in adults. Scientific Reports, 11, 20152.
38. Michelle D. Pang, Jacco J, Yvonne M, Joanne A, Louise K, Jason C. Tanja C, Anne R, Vera B, Gijs H., and | Ellen E. (2023). The effect of weight loss on whole-body and tissue-specific insulin sensitivity and hepatic lipid content and composition: SWEET sub study. Obesity (Silver Spring). V 31:1745–1754.
39. Deng, L., Long Jia, Xiao-Li Wu, Ming Cheng (2025). Association between body mass index and glycemic control in T2DM. Diabetes & Metabolism Journal, 49(3), 409–420.
40. Can Gan, Yuan Yuan, H. Shen, Jinhang Gao, Xiangxin K, Zhaodi Che, Yangkun Guo, Hua Wang, Erdan Dong, and Jia Xiao (2025). Liver diseases: epidemiology, causes, trends, and predictions. Signal Transduction and Targeted Therapy, vol 10, p. 33.
41. Kenneth Cusi et al. (2022). American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocrine Practice, vol 28, p: 528e562.
42. Liliana Paula Bricarello et al. (2025). Association between animal protein intake and overweight/obesity: A systematic review and meta-analysis of observational studies. Nutrition, Metabolism and Cardiovascular Diseases Volume 35, Issue 8, p: 104027.
43. Carmen Lara-Romero and Manuel Romero-Gómez (2024). Treatment Options and Continuity of Care in Metabolically Associated Fatty Liver Disease: A Multidisciplinary Approach. European Cardiology Review 19: e06.
44. Sitara Niranjan, Brett E. Phillips, and Nick Annoukakis (2023). Uncoupling hepatic insulin resistance – hepatic inflammation to improve insulin sensitivity and to prevent impaired metabolism associated with fatty liver disease in type 2 diabetes. Frontiers in Endocrinology.